Benzodiazepine, psychotropic medication, and dementia: A population-based cohort study

Area of Science:

• Gerontology
• Neuroscience
• Pharmacology

Background:

• Benzodiazepine (BZD) use is linked to dementia risk, but specific associations with half-life and other psychotropic drugs require clarification.
• Understanding these associations is crucial for geriatric pharmacotherapy and dementia prevention strategies.

Purpose of the Study:

• To investigate the association between benzodiazepine half-life, psychotropic drug use, and the risk of developing dementia in older adults.
• To differentiate the dementia risk associated with short versus long half-life benzodiazepines.

Main Methods:

• A prospective cohort study involving 8240 individuals aged 65 and older.
• Medication use was assessed via interviews, and incident dementia cases were confirmed through a rigorous multi-step procedure by an endpoint committee.
• Follow-up duration was a mean of 8 years, during which 830 dementia cases were identified.

Main Results:

• Benzodiazepine users showed a 10% increased dementia risk (HR 1.10).
• Long half-life benzodiazepine users exhibited a significantly higher dementia risk (HR 1.62) compared to short half-life users (HR 1.05).
• Psychotropic drug users also demonstrated an elevated dementia risk (HR 1.47).

Conclusions:

• Long half-life benzodiazepines are associated with a marked increase in dementia risk among older adults.
• Use of psychotropic medications is also linked to an increased risk of dementia.
• These findings underscore the importance of cautious prescribing of long half-life benzodiazepines and other psychotropic drugs in the elderly population.